Cell-Based P53 Reporter Assay Provides Insight for Pre-Clinical Cancer Drug Discovery State College, PA (September 27, 2022) – INDIGO Biosciences announced today the addition of a new cell-based luciferase reporter assay for Human Tumor Protein P53. The new assay is part of INDIGO’s portfolio of assays for cancer research. The bioscience company’s cell-based luciferase reporterRead More
New Activator Protein 1 (AP-1) Assay from INDIGO Biosciences
Activator Protein 1 (AP-1) Assay Provides Researchers with Insight into Cancer and Inflammation State College, PA (August 29, 2022) – INDIGO Biosciences announced today the addition of a new cell-based firefly luciferase reporter assay for the Human Activator Protein 1 (AP-1) transcription factor. The new assay augments INDIGO’s existing collection of related transcription factor assaysRead More
INDIGO Biosciences Develops Two New Progesterone Receptor Ortholog Assays
Rabbit PGR and Cynomolgus Monkey PGR Assays Grow INDIGO’s Ortholog Assays to Over Forty State College, PA (11 July 2022) – INDIGO Biosciences announced today the expansion of its portfolio of ortholog assays with two new progesterone receptor assays. INDIGO’s newest offerings include reporter assay systems for Cynomolgus Monkey Progesterone Receptor (NR3C3, PGR, PR) andRead More
INDIGO Biosciences Offers New Assay to Test Development and Oncology Therapeutics
INDIGO Offers Human Estrogen-related Receptor Beta Assay as a Commercial Assay for the First Time State College, PA (17 May 2022) – INDIGO Biosciences, the recognized industry leader in nuclear receptor reporter assays, announced today the expanding of their robust preclinical testing portfolio of cell-based reporter assays to include the Human Estrogen-related Receptor Beta (NR3B2;Read More